Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
APRETUDE - cabotegravir kit
Product / population
APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.
Renal method
CrCl, mL/min; source subsection does not name an equation
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-10
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Prevention and combination HIV treatment have different renal wording
APRETUDE and CABENUVA are not interchangeable products. HIV testing remains essential before each APRETUDE injection.
What to reconcile: Confirm the product, indication and acute-infection testing. Do not infer a dialysis supplement from protein binding.
DailyMed / ViiV Healthcare Company · APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.
Renal method: CrCl, mL/min; source subsection does not name an equation Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-10
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No renal adjustment is required at CrCl 15 to below 90 mL/min, based on studies of oral cabotegravir. The effects in ESRD without dialysis are unknown. High protein binding makes dialysis unlikely to alter exposure; this does not establish a supplemental dialysis dose.
Confirm negative HIV-1 status before initiation and before every injection using testing appropriate for acute/primary infection. APRETUDE is prevention, not a complete treatment regimen for established HIV-1. Apply the full eligibility and missed-injection instructions separately.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.